Trial Outcomes & Findings for Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (NCT NCT00345865)
NCT ID: NCT00345865
Last Updated: 2020-07-14
Results Overview
Progression is defined using the Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group.The definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
473 participants
Primary outcome timeframe
1 year
Results posted on
2020-07-14
Participant Flow
Participant milestones
| Measure |
NHL With Irradiation
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
171
|
149
|
2
|
5
|
146
|
|
Overall Study
COMPLETED
|
171
|
149
|
2
|
5
|
146
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Baseline characteristics by cohort
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
Total
n=473 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
4 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
17 Participants
n=8 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
126 Participants
n=5 Participants
|
129 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
107 Participants
n=21 Participants
|
368 Participants
n=8 Participants
|
|
Age, Categorical
>=65 years
|
41 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
39 Participants
n=21 Participants
|
88 Participants
n=8 Participants
|
|
Sex: Female, Male
Female
|
53 Participants
n=5 Participants
|
74 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
54 Participants
n=21 Participants
|
183 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
118 Participants
n=5 Participants
|
75 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
92 Participants
n=21 Participants
|
290 Participants
n=8 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Asian
|
4 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
9 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Black or African American
|
10 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
20 Participants
n=8 Participants
|
|
Race (NIH/OMB)
White
|
147 Participants
n=5 Participants
|
127 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
135 Participants
n=21 Participants
|
415 Participants
n=8 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
9 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
24 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: 1 yearProgression is defined using the Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group.The definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy.
Outcome measures
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Number of Participants With 1 Year Progression Free Survival
|
112 Participants
|
102 Participants
|
1 Participants
|
2 Participants
|
116 Participants
|
PRIMARY outcome
Timeframe: 2 yearsProgression is determined using Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group. Definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy.
Outcome measures
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Number of Participants With 2 Years Progression Free Survival
|
96 Participants
|
91 Participants
|
1 Participants
|
1 Participants
|
106 Participants
|
PRIMARY outcome
Timeframe: 1 yearOutcome measures
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Number of Participants With 1 Year Overall Survival
|
139 Participants
|
144 Participants
|
1 Participants
|
5 Participants
|
128 Participants
|
PRIMARY outcome
Timeframe: 2 yearsOutcome measures
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Number of Participants With 2 Years Overall Survival
|
124 Participants
|
140 Participants
|
1 Participants
|
4 Participants
|
121 Participants
|
SECONDARY outcome
Timeframe: Day 42return to ANC (absolute neutrophil count) more than 500 cells/milliliter.
Outcome measures
| Measure |
NHL With Irradiation
n=171 Participants
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 Participants
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 Participants
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=145 Participants
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Number of Participants With Hematopoietic Recovery After Transplantation
|
171 Participants
|
147 Participants
|
2 Participants
|
5 Participants
|
145 Participants
|
Adverse Events
NHL With Irradiation
Serious events: 34 serious events
Other events: 125 other events
Deaths: 47 deaths
HL Without Irradiation
Serious events: 18 serious events
Other events: 98 other events
Deaths: 9 deaths
NHL - HIV Infected With Irradiation
Serious events: 1 serious events
Other events: 2 other events
Deaths: 1 deaths
NHL - HIV Infected Without Irradiation
Serious events: 1 serious events
Other events: 2 other events
Deaths: 1 deaths
NHL Without Radiation and Cyclophosphamide
Serious events: 0 serious events
Other events: 120 other events
Deaths: 25 deaths
Serious adverse events
| Measure |
NHL With Irradiation
n=171 participants at risk
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 participants at risk
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 participants at risk
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 participants at risk
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 participants at risk
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death
|
2.3%
4/171 • Number of events 4 • 2 years
|
0.00%
0/149 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Hemorrhage
|
0.58%
1/171 • Number of events 1 • 2 years
|
0.00%
0/149 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Disease progression
|
5.3%
9/171 • Number of events 12 • 2 years
|
2.7%
4/149 • Number of events 4 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Relapse
|
7.0%
12/171 • Number of events 12 • 2 years
|
8.1%
12/149 • Number of events 12 • 2 years
|
0.00%
0/2 • 2 years
|
20.0%
1/5 • Number of events 1 • 2 years
|
0.00%
0/146 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary failure
|
0.58%
1/171 • Number of events 1 • 2 years
|
0.00%
0/149 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplasia
|
0.58%
1/171 • Number of events 1 • 2 years
|
0.00%
0/149 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death due to progression
|
2.3%
4/171 • Number of events 4 • 2 years
|
0.67%
1/149 • Number of events 1 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death due to relapse
|
4.7%
8/171 • Number of events 8 • 2 years
|
0.67%
1/149 • Number of events 1 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death due to multi organ failure
|
0.58%
1/171 • Number of events 1 • 2 years
|
0.67%
1/149 • Number of events 1 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.00%
0/146 • 2 years
|
Other adverse events
| Measure |
NHL With Irradiation
n=171 participants at risk
Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
HL Without Irradiation
n=149 participants at risk
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected With Irradiation
n=2 participants at risk
Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
|
NHL - HIV Infected Without Irradiation
n=5 participants at risk
Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
|
NHL Without Radiation and Cyclophosphamide
n=146 participants at risk
Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
|
|---|---|---|---|---|---|
|
Infections and infestations
Infection
|
55.0%
94/171 • Number of events 331 • 2 years
|
42.3%
63/149 • Number of events 187 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
40.0%
2/5 • Number of events 15 • 2 years
|
70.5%
103/146 • Number of events 291 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia
|
39.2%
67/171 • Number of events 160 • 2 years
|
35.6%
53/149 • Number of events 102 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
40.0%
2/5 • Number of events 6 • 2 years
|
37.7%
55/146 • Number of events 102 • 2 years
|
|
Cardiac disorders
Decreased heart function
|
11.7%
20/171 • Number of events 26 • 2 years
|
10.7%
16/149 • Number of events 21 • 2 years
|
0.00%
0/2 • 2 years
|
40.0%
2/5 • Number of events 3 • 2 years
|
13.7%
20/146 • Number of events 31 • 2 years
|
|
Nervous system disorders
Neuropathy
|
17.0%
29/171 • Number of events 39 • 2 years
|
8.1%
12/149 • Number of events 13 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
9.6%
14/146 • Number of events 16 • 2 years
|
|
Renal and urinary disorders
Other Kidney disorder
|
13.5%
23/171 • Number of events 36 • 2 years
|
4.0%
6/149 • Number of events 10 • 2 years
|
50.0%
1/2 • Number of events 2 • 2 years
|
40.0%
2/5 • Number of events 2 • 2 years
|
6.2%
9/146 • Number of events 10 • 2 years
|
|
Nervous system disorders
sensory loss
|
11.7%
20/171 • Number of events 26 • 2 years
|
2.7%
4/149 • Number of events 4 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
5.5%
8/146 • Number of events 8 • 2 years
|
|
Vascular disorders
Deep vein thrombosis
|
5.3%
9/171 • Number of events 10 • 2 years
|
5.4%
8/149 • Number of events 9 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
0.00%
0/5 • 2 years
|
10.3%
15/146 • Number of events 16 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Intubation
|
5.3%
9/171 • Number of events 17 • 2 years
|
4.0%
6/149 • Number of events 8 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
4.1%
6/146 • Number of events 7 • 2 years
|
|
Vascular disorders
Thrombosis
|
5.8%
10/171 • Number of events 10 • 2 years
|
5.4%
8/149 • Number of events 9 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
0.00%
0/5 • 2 years
|
5.5%
8/146 • Number of events 10 • 2 years
|
|
Gastrointestinal disorders
GI bleeding
|
7.0%
12/171 • Number of events 13 • 2 years
|
2.0%
3/149 • Number of events 4 • 2 years
|
50.0%
1/2 • Number of events 1 • 2 years
|
20.0%
1/5 • Number of events 2 • 2 years
|
3.4%
5/146 • Number of events 6 • 2 years
|
|
Metabolism and nutrition disorders
deconditioning
|
4.1%
7/171 • Number of events 11 • 2 years
|
1.3%
2/149 • Number of events 2 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
4.8%
7/146 • Number of events 9 • 2 years
|
|
Injury, poisoning and procedural complications
Surgery
|
2.9%
5/171 • Number of events 8 • 2 years
|
2.0%
3/149 • Number of events 3 • 2 years
|
0.00%
0/2 • 2 years
|
20.0%
1/5 • Number of events 1 • 2 years
|
3.4%
5/146 • Number of events 6 • 2 years
|
|
Endocrine disorders
hypothyroidism
|
5.3%
9/171 • Number of events 10 • 2 years
|
6.7%
10/149 • Number of events 11 • 2 years
|
0.00%
0/2 • 2 years
|
0.00%
0/5 • 2 years
|
0.68%
1/146 • Number of events 1 • 2 years
|
Additional Information
Dr.Veronika Bachanova
Masonic Cancer Center, University of Minnesota
Phone: 612-625-5469
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place